ZELBORAF® developed by Roche (vemurafenib) tablets are indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
ZELBORAF is not indicated for use in patients with wild-type BRAF melanoma.
ZELBORAF® (vemurafenib) is indicated for the treatment of patients with Erdheim-Chester Disease (ECD) with BRAF V600 mutation.